Cross-reactivity in β-Lactam Allergy
The Journal of Allergy and Clinical Immunology: In Practice, ISSN: 2213-2198, Vol: 6, Issue: 1, Page: 72-81.e1
2018
- 164Citations
- 24Usage
- 256Captures
- 3Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations164
- Citation Indexes159
- 159
- CrossRef9
- Policy Citations5
- Policy Citation5
- Usage24
- Abstract Views24
- Captures256
- Readers256
- 256
- Mentions3
- News Mentions3
- News3
Most Recent News
Cefuroxime is a safe alternative for penicillin allergic patients
13 Jun 2024 Posted at 11:29h in Blog, Drug Assessments by jauca The BC Centre for Disease Control (BCCDC) is collaborating with the UBC Therapeutics
Article Description
β-Lactam drugs (penicillins, amoxicillin, and cephalosporins) account for 42.6% of all severe drug-induced anaphylaxis. In this review, we focus on clinically significant immunologic cross-reactivity in patients with confirmed penicillin allergy to cephalosporins, and the structural involvement of the R 1 and R 2 chemical side chains of the cephalosporins causing IgE-mediated cross-reactivity with penicillin and other cephalosporins. Skin tests predict IgE-mediated reactions and showed cross-reactivity between penicillins and early generation cephalosporins that shared side chains, but confirmatory challenge data are lacking. Later-generation cephalosporins, which have distinct side chains, do not have any skin test cross-reactivity with penicillin/amoxicillin. There is debate as to the involvement of R 2 side chains as the antigenic determinants that cause IgE-mediated hypersensitivity with various cephalosporins. Avoidance of cephalosporins, when they are the drug of choice in a penicillin-allergic individual, results in significant morbidity that outweighs the low risk of anaphylaxis. We conclude that there is ample evidence to allow the safe use of cephalosporins in patients with isolated confirmed penicillin or amoxicillin allergy.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2213219817307110; http://dx.doi.org/10.1016/j.jaip.2017.08.027; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85030637138&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/29017833; https://linkinghub.elsevier.com/retrieve/pii/S2213219817307110; https://scholar.rochesterregional.org/rrhpubs/1052; https://scholar.rochesterregional.org/cgi/viewcontent.cgi?article=2052&context=rrhpubs; https://dx.doi.org/10.1016/j.jaip.2017.08.027; http://www.jaci-inpractice.org/article/S2213-2198(17)30711-0/abstract?utm_content=buffer5ef45&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer; http://www.jaci-inpractice.org/article/S2213219817307110/abstract; http://www.jaci-inpractice.org/article/S2213219817307110/fulltext; http://www.jaci-inpractice.org/article/S2213219817307110/pdf; https://www.jaci-inpractice.org/article/S2213-2198(17)30711-0/abstract
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know